Clinical trial
Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory…
NCT00113204 · Infinity Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00113204 |
|---|---|
| Title | Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma |
| Official title | A Phase 1, Safety Assessment and Pharmacokinetic Study of IPI-504 in Patients With Relapsed, and Relapsed Refractory Multiple Myeloma |
| Acronym | IPi-504-01 |
| Lead sponsor | Infinity Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | IPI-504 |
| Enrollment | 18 |
| Start date | Jun 1, 2005 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Jun 7, 2005 |
| Last update posted | May 20, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: